LECANEMAB RECEIVES PRIORITY REVIEW STATUS IN JAPAN

/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...

Related Keywords

China ,Japan ,Tokyo ,Cambridge ,Cambridgeshire ,United Kingdom ,Massachusetts ,United States ,Japanese ,Haruo Naito ,Charles Weissmann ,Walter Gilbert ,Heinz Schaller ,Libby Holman ,Christophera Viehbacher ,Mike Hencke ,Natacha Gassenbach ,Kenneth Murray ,Prnewswire Eisai Co Ltd ,Linkedin ,Twitter ,Investor Relations Department ,National Institute On ,Biogen Inc ,Nasdaq ,Facebook ,Public Relations Department ,National Institutes Of Health ,Drug Administration ,Eisai Inc ,Washington University School Of Medicine ,Exchange Commission ,Eisai Co Ltd ,Youtube ,Japanese Ministry Of Health ,Alzheimer Network Trials Unit ,European Medicines Agency ,National Medical Products Administration ,United Nations Sustainable Development Goals Sdgs ,Devices Agency ,Alzheimer Clinical Trial Consortium ,Priority Review ,Japanese Ministry ,Medical Devices Agency ,New England Journal ,Supplemental Biologics License Application ,About Priority Review ,Brand Name ,Prescribing Informationin ,Clinical Trial Consortium ,National Institute ,National Institutes ,Tau Nexgen ,Dominantly Inherited ,Washington University School ,Corporate Concept ,United Nations Sustainable Development Goals ,Sir Kenneth Murray ,Nobel Prize ,Private Securities Litigation Reform Act ,Catches Eyes ,